Vancenase AQ advisory committee review postponed at Schering-Plough's request.
This article was originally published in The Tan Sheet
Executive Summary
SCHERING-PLOUGH VANCENASE AQ ADVISORY COMMITTEE REVIEW POSTPONED at the company's request. Review of Schering's Rx-to-OTC switch application for Vancenase AQ (beclomethasone dipropionate) nasal spray by FDA's Nonprescription Drugs and Pulmonary-Allergy Advisory Committees had been scheduled for Oct. 11. The company is seeking approval of the drug as an OTC treatment for seasonal allergic rhinitis ("The Tan Sheet" Sept. 9, p. 1).